Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Ceribell (CBLL) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ceribell (CBLL) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
CFO Scott Blumberg will join a fireside chat in New York City at 7:00 a.m. PST / 10:00 a.m. EST. A live and archived webcast will be available in the Investor Relations section of Ceribell's website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.
Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Wednesday, November 11, 2026
Time: 7:00 a.m. PST / 10:00 a.m. EST
A live and archived webcast of the fireside chat will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and monitoring delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit https://www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com
Media Contact
Laura Hartlieb
Press@ceribell.com
